<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some dominant <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e>, <z:mp ids='MP_0001799'>viral</z:mp> processes and neoplastic disorders base their pathogenicity on the production of protein or proteins that negatively affect cellular metabolism or environment </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, the inhibition of the synthesis of those proteins should prevent the biological damage </plain></SENT>
<SENT sid="2" pm="."><plain>A promising approach to decreasing the level of the abnormal protein(s) is represented by specific interference with gene expression at the level of <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The specific suppression of the expression of an <z:chebi fb="2" ids="33699">mRNA</z:chebi> can be achieved by using ribozymes </plain></SENT>
<SENT sid="4" pm="."><plain>Ribozymes are <z:chebi fb="40" ids="33697">RNA</z:chebi> molecules able to break and form covalent bonds within a nucleic acid molecule </plain></SENT>
<SENT sid="5" pm="."><plain>These molecules, with even greater potential advantages than antisense oligodeoxynucleotides, are able to bind specifically and cleave an <z:chebi fb="2" ids="33699">mRNA</z:chebi> substrate </plain></SENT>
<SENT sid="6" pm="."><plain>There are advantages to using ribozymes instead of antisense oligodeoxynucleotides </plain></SENT>
<SENT sid="7" pm="."><plain>Ribozymes can inactivate the target <z:chebi fb="40" ids="33697">RNA</z:chebi> without relying on the host cell's machinery and they have the capacity to cleave more than one copy of the target <z:chebi fb="40" ids="33697">RNA</z:chebi> by dissociating from the cleavage products and binding to another target molecule </plain></SENT>
<SENT sid="8" pm="."><plain>Most of the studies performed to date have described the use of ribozymes as therapeutic agents for <z:mp ids='MP_0001799'>viral</z:mp> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diseases </plain></SENT>
<SENT sid="9" pm="."><plain>However, some dominant <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> may also benefit from this approach </plain></SENT>
<SENT sid="10" pm="."><plain>This is the case for some <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorders</z:e> such as <z:e sem="disease" ids="C0029434" disease_type="Disease or Syndrome" abbrv="">osteogenesis imperfecta</z:e>, <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and the craniosynostotic syndromes </plain></SENT>
</text></document>